A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects
A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effects of RS-C1001 Tablets in Chinese Healthy Subjects
Peking University First Hospital
72 participants
Sep 25, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effects of RS-C1001 tablets in Chinese healthy subjects. This study will consist of two parts (Parts A and B). 42 subjects have been planned for Part A and 30 subjects for Part B.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Subjects will receive RS-C1001 tablets orally as a single ascending dose
Subjects will receive RS-C1001 tablets orally as a multiple ascending dose
Subjects will receive RS-C1001 tablets orally as a single dose after intake of a high-calorie, high-fat breakfast
Subjects will receive placebo matching tne RS-C1001 dose orally as a single ascending dose
Subjects will receive placebo matching tne RS-C1001 dose orally as a multiple ascending dose
Subjects will receive placebo matching tne RS-C1001 dose orally as a single dose after intake of a high-calorie, high-fat breakfast
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06669429